open access

Vol 23, No 1 (2018)
Original research articles
Published online: 2018-01-01
Submitted: 2017-08-23
Get Citation

Treatment outcomes and late toxicities of intensity-modulated radiation therapy for 1091 Japanese patients with localized prostate cancer

Hidekazu Tanaka, Takahiro Yamaguchi, Kae Hachiya, Shingo Kamei, Satoshi Ishihara, Masahide Hayashi, Shinichi Ogawa, Hironori Nishibori, Satoshi Goshima, Masayuki Matsuo
DOI: 10.1016/j.rpor.2017.11.002
·
Rep Pract Oncol Radiother 2018;23(1):28-33.

open access

Vol 23, No 1 (2018)
Original research articles
Published online: 2018-01-01
Submitted: 2017-08-23

Abstract

Aim

This study aimed to evaluate the treatment result of intensity-modulated radiation therapy (IMRT) in a large number of Japanese patients with prostate cancer.

Background

A total of 1091 patients with localized prostate cancer were recruited between March 2006 and July 2014. The patients were stratified into low- (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]205 [18.8%]), intermediate- (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]450 [41.2%]), high- (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]345 [31.6%]), and very high-risk (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]91 [8.3%]) groups according to the National Comprehensive Cancer Network classification. All patients were irradiated via IMRT at a dose of 74–78[[ce:hsp sp="0.25"/]]Gy with or without androgen-deprivation therapy. The mean follow-up period was 50 months (range, 2–120 months).

Results

The biochemical failure-free rate (BFFR), the clinical failure-free rate, and the overall survival rate at the 5-year follow-up for all patients was 91.3%, 96.2%, and 99.1%, respectively. In univariate analysis, the prostate-specific antigen (PSA) levels (≤20 vs. >20[[ce:hsp sp="0.25"/]]ng/ml) were significantly correlated with BFFR. A trend toward higher BFFR was noted in patients with a Gleason score (GS) of ≤7 than in patients with GS ≥8. In multivariate analysis, only PSA (≤20 vs. >20[[ce:hsp sp="0.25"/]]ng/ml) was significantly correlated with BFFR. The cumulative incidence rate of gastrointestinal and genitourinary toxicity (≥grade 2) at the 5-year follow-up was 11.4% and 4.3%, respectively.

Conclusions

The findings of this study indicate that IMRT is well tolerated and is associated with both good long-term tumor control and excellent outcomes in patients with localized prostate cancer.

Abstract

Aim

This study aimed to evaluate the treatment result of intensity-modulated radiation therapy (IMRT) in a large number of Japanese patients with prostate cancer.

Background

A total of 1091 patients with localized prostate cancer were recruited between March 2006 and July 2014. The patients were stratified into low- (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]205 [18.8%]), intermediate- (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]450 [41.2%]), high- (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]345 [31.6%]), and very high-risk (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]91 [8.3%]) groups according to the National Comprehensive Cancer Network classification. All patients were irradiated via IMRT at a dose of 74–78[[ce:hsp sp="0.25"/]]Gy with or without androgen-deprivation therapy. The mean follow-up period was 50 months (range, 2–120 months).

Results

The biochemical failure-free rate (BFFR), the clinical failure-free rate, and the overall survival rate at the 5-year follow-up for all patients was 91.3%, 96.2%, and 99.1%, respectively. In univariate analysis, the prostate-specific antigen (PSA) levels (≤20 vs. >20[[ce:hsp sp="0.25"/]]ng/ml) were significantly correlated with BFFR. A trend toward higher BFFR was noted in patients with a Gleason score (GS) of ≤7 than in patients with GS ≥8. In multivariate analysis, only PSA (≤20 vs. >20[[ce:hsp sp="0.25"/]]ng/ml) was significantly correlated with BFFR. The cumulative incidence rate of gastrointestinal and genitourinary toxicity (≥grade 2) at the 5-year follow-up was 11.4% and 4.3%, respectively.

Conclusions

The findings of this study indicate that IMRT is well tolerated and is associated with both good long-term tumor control and excellent outcomes in patients with localized prostate cancer.

Get Citation

Keywords

Prostate cancer; Intensity-modulated radiation therapy; External beam radiation therapy

About this article
Title

Treatment outcomes and late toxicities of intensity-modulated radiation therapy for 1091 Japanese patients with localized prostate cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 23, No 1 (2018)

Pages

28-33

Published online

2018-01-01

DOI

10.1016/j.rpor.2017.11.002

Bibliographic record

Rep Pract Oncol Radiother 2018;23(1):28-33.

Keywords

Prostate cancer
Intensity-modulated radiation therapy
External beam radiation therapy

Authors

Hidekazu Tanaka
Takahiro Yamaguchi
Kae Hachiya
Shingo Kamei
Satoshi Ishihara
Masahide Hayashi
Shinichi Ogawa
Hironori Nishibori
Satoshi Goshima
Masayuki Matsuo

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl